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umc.nl (CAbstract Aims: Pre-operative radiotherapy has proven to reduce local recurrences after cura-
tive surgery for rectal cancer. Radiotherapy is generally well tolerated, although postoperative
morbidity and mortality was increased in some patients. Current study was undertaken to
analyse whether the interval between preoperative radiotherapy and surgery inﬂuences post-
operative mortality and recurrence for two cohorts.
Methods: All Dutch patients included in the total mesorectal excision (TME)-trial receiving
radiotherapy for resectable rectal cancer were included in this study (n = 642). The veriﬁcation
set consisted of all patients receiving short-course radiotherapy for resectable rectal cancer in
two radiotherapy clinics in The Netherlands (n = 600). Univariate and multivariable survival
analyses for overall survival, disease-free survival, local recurrence-free survival and non-
cancer related survival were calculated.
Results: Patients aged 75 years and older treated during the TME-trial showed a worse overall
and non-cancer-related survival when surgically treated 4–7 days after the last fraction of
radiotherapy. No differences in survival between the interval groups were found in the veriﬁ-
cation set.
Conclusion: Present study found that elderly patients aged 75 years and older operated
4–7 days after the last fraction of radiotherapy had a higher chance of dying due to non-
cancer-related causes during the TME-trial as compared to patients with an interval of
0–3 days. In the veriﬁcation set similar differences could not be conﬁrmed, which could belsevier Ltd. All rights reserved.
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er Society and the Dutch National Health Council.
artment of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC
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3132 C.B.M. van den Broek et al. / European Journal of Cancer 49 (2013) 3131–3139due to awareness of the clinicians who avoided delayed surgery after radiotherapy since the
results have been presented during congresses. A longer than recommended interval between
radiotherapy and surgery should be avoided. Besides, the veriﬁcation set suggests that radio-
therapy duration of 7 days is acceptable.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
In the treatment of rectal cancer, local recurrences
are a major problem, occurring in 15–45% of the rectal
cancer patients without total mesorectal excision
(TME) surgery and radiotherapy.1–4 These local recur-
rences often have severe disabling symptoms and are
diﬃcult to treat. To reduce local recurrences after
curative surgery, several studies have used either pre-
operative or postoperative radiotherapy.5,6 In a large
Swedish trial, short-course preoperative RT has proven
to be more eﬀective compared to postoperative radio-
therapy with conventional surgery.7 The TME-trial
and the CR07 trial showed, additionally, that with
total mesorectal excision (TME) surgery, preoperative
radiotherapy improved local control even further.8,9
Preoperative radiotherapy has been given in varying
regimens, either short-course (25 Gy in 5 fractions dur-
ing one week) or long course combined with chemo-
therapy (45–50 Gy during 5 weeks).6,10 Radiotherapy
is generally well tolerated, although postoperative
morbidity and mortality is increased in some
patients.8,11–16 The increased postoperative mortality
may be contributed to the use of anterior–posterior
beams, resulting in large irradiated volumes, from the
earlier trials.11,13
A more recent study has shown that short-course
radiotherapy has signiﬁcant impact on the perioperative
leucocyte response.17 Short-course radiotherapy fol-
lowed by surgery after 5 or more days since the last frac-
tion of radiotherapy was signiﬁcantly correlated with
leucopenia or falling leucocytes rates on day one postop-
eratively. The patients with an abnormal leucocyte
response developed sepsis more often (31% versus 13%
in patients with a normal leucocyte response), and had
an increased risk of death within 90 days after surgery
compared to patients with a normal leucocyte response,
suggesting that surgery should occur within 5 days after
the last day of radiotherapy.
This study was undertaken to analyse whether the
interval between preoperative radiotherapy and surgery,
or the duration of radiotherapy (5 or 7 days) inﬂuences
the outcome of patients regarding one year post-opera-
tive mortality and ﬁve year local recurrence free survival
and disease free survival for two cohorts; patients from
the TME-trial from 1996 to 1999 (DUT-KWF-CKVO-
9504, EORTC-40971, EU-96020) and patients from a
more recent cohort from 2000 until 2010 as a veriﬁcation
set.2. Methods
2.1. Patients and follow-up
2.1.1. Dataset from the TME-trial
From January 1996 until December 1999 1861
patients with resectable rectal cancer without evidence
of distance disease were randomly assigned to TME
preceded by 5  5 Gy radiotherapy or TME alone.
There was no age limitation. For this subset analysis,
only Dutch patients receiving pre-operative radiother-
apy are included (n = 642), since the follow-up of the
Dutch patients has been more thorough and complete.
2.1.2. Veriﬁcation set
From January 2000 until 15th July 2010, all patients
receiving short-course preoperative radiotherapy for
resectable rectal cancer without evidence of distant
metastases followed by TME surgery at Leiden Univer-
sity Medical Center and Catherina Hospital Eindhoven
were included retrospectively. Information on the
patients’ characteristics, such as gender and date of
birth, as well as tumour characteristics, location
(according to the International Classiﬁcation of Dis-
eases for Oncology (ICD-O)), histology, stage (clinical
and pathological TNM classiﬁcation 5th edition), grade
and primary treatment, were obtained from the medical
records. The vital status was obtained either directly
from the patients’ medical record or through linkage
of the hospital with the municipal population registry
which records information on their inhabitants’ vital
status. Exclusion criteria were: patients without infor-
mation available on their vital status (n = 2), patients
without information on the date of radiotherapy or sur-
gery (n = 30) and missing data on the age (n = 2).
For both datasets, stage was based on pathological
TNM classiﬁcation. For patients in whom pathological
stage was unknown, clinical stage was used. Patients
were divided in two age groups (<75 years and
P75 years). The majority of the patients were operated
1, 2, 3, 4 or 5 days after the last fraction of radiotherapy.
To compare the eﬀect of the interval, we have divided
the patients into four groups. Patients operated within
3 days since the last day of radiotherapy, from 4 until
7 days, from 8 until 27 days and from 28 days or more
(in line with one of the arms of the Stockholm III
trial18). Radiotherapy duration has been divided into
two groups: 5 days (Monday till Friday) or 7 days of
radiotherapy (with a weekend included). Overall
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divided into two groups: OTT 610 days (with the excep-
tion of a radiotherapy duration of 8 days) or OTT
>10 days (as shown in Tables 1a and 1b with the light
grey shaded area). A radiotherapy duration of 8 days
was in violation with the protocol and has therefore
been included as an OTT >10 days. An interval between
radiotherapy and surgery P8 days (dark shaded grey
area in Tables 1a and 1b) has been excluded from the
OTT analyses since this was in violation with the
recommendations.
When patients received radiotherapy for 5 days, from
Monday till Friday, surgery was either performed on
Monday (within 3 days since the last fraction ofFig. 1. Relation between duration of radiotherapy, interval bet
Table 1a
Relation between radiotherapy duration and the interval between radiothe
The area is light grey shaded area in case of OTT >10 days, and the dark sh
violation with the protocol. Radiation duration of 8 days was in violatio
OTT >10 days.
Table 1b
Relation between radiotherapy duration and the interval between radiothe
The area is light grey shaded area in case of OTT >10 days, and the dark sh
violation with the recommendations. Radiation duration of 8 days was in v
the OTT >10 days.radiotherapy), or later in that week (from 4 until 7 days
since the last fraction of radiotherapy).
2.2. Statistical analyses
All analyses were performed with STATA 10. Diﬀer-
ences between the groups were tested with a Chi-
Squared test. Follow-up was calculated as the time from
surgery to death or date of last contact. Overall survival,
disease-free survival, local recurrence-free survival and
non-cancer related survival (including death due to
post-operative complications) were calculated, by using
Kaplan–Meier survival curves, for both univariate and
multivariable survival analyses. Overall survival andween radiotherapy and surgery and overall treatment time.
rapy and surgery during the total mesorectal excision (TME)-trial.
aded grey area has been excluded from the OTT analyses. Both were in
n with the protocol and these patients were therefore included in the
rapy and surgery during the veriﬁcation set (2000 until 2010).
aded grey area has been excluded from the OTT analyses. Both were in
iolation with the protocol and these patients were therefore included in
3134 C.B.M. van den Broek et al. / European Journal of Cancer 49 (2013) 3131–3139non-cancer related mortality were truncated at one year,
since recently a study has shown that post-operative
mortality can be increased up to one year after surgery
due to diﬀerences in comorbidities and fragility.19 Dis-
ease-free survival and local recurrence-free survival were
truncated at 5 years, since recurrences or metastases are
not expected to occur often within one year after sur-
gery. Univariate and multivariable survival analysis
was performed using a Cox proportional hazard model.
Statistical signiﬁcance was deﬁned as p < 0.05. All anal-
yses are done separately for the group of patients from
the TME trial and the veriﬁcation set.3. Results
3.1. Dataset from the TME-trial
3.1.1. Patients
A total of 642 patients from the TME-trial were
included in this study. The median follow-up since
surgery of these patients was 9.1 years (range 0.01–
13.7 years). The median age of the patients at time of
surgery was 65.1 years (range 26.6–89.0 years).3.1.2. Radiotherapy duration and interval between
radiotherapy and surgery
Table 1a demonstrates the relationship between the
duration of radiotherapy and the interval between the
last fraction of radiotherapy and surgery for patients
during the TME-trial. Most patients received radiother-
apy from Monday till Friday, so 5 days continuously
(85.0%). For the other patients the radiotherapy dura-
tion was 6 days (2.6%), 7 days (9.8%) or 8 days (2.5%);
including a weekend and/or bank holiday. Surgery
within 3 days of the last fraction of radiotherapy was
performed in 293 patients of the 642 patients, an interval
of 4–7 days was the most common (340/642). IntervalsTable 2a
Clinical characteristics of patients of the total mesorectal excision (TME)-
Interval between radiotherapy and surgery
63 days 4–7 days
n % n %
Age
<75 years 237 45.1 279 53.1
P75 years 56 47.9 61 52.1
Sex
Male 185 44.3 228 54.5
Female 108 48.2 112 50.0
Stage
0 3 30.0 5 50.0
I 102 48.2 106 50.0
II 94 49.5 96 50.5
III 94 40.9 133 57.8
Total 293 45.6 340 53.0of 8 until 27 days and 28 days or more occurred less
often (5 and 4 patients, respectively).
In Table 2a the characteristics of the patients divided
into the four interval groups are shown. There were no
signiﬁcant diﬀerences between the four interval groups
in age and gender during the TME-trial (p = 0.5 and
p = 0.2, respectively). Pathological stage was lower in
the patients with an interval of P8 days as compared
to patients with an interval of <8 days (p < 0.001), but
no diﬀerence was detected between the group of patients
with an interval of 0–3 days and 4–7 days (p = 0.3), nei-
ther when the interval of 28 days and more only was
excluded (p = 0.4).3.1.3. Survival
Due to small numbers in the interval group of 8 until
27 days and 28 days or more, these patients (n = 9) were
excluded for survival analysis. 30-day mortality analyses
showed no signiﬁcant diﬀerence between an interval of
0–3 days and 4–7 days for all ages combined (30-day
mortality for interval of 0–3 days was 2.1% and for the
interval of 4–7 days 4.7%, p = 0.08). Neither diﬀerence
in one-year overall survival between an interval of
0–3 days and 4–7 days was found for all ages combined
(hazard ratio (HR) 1.67; 95% conﬁdence interval (CI)
0.94–2.96; p = 0.08). However, the 1-year overall sur-
vival showed an age disparity (Fig. 2a). Where patients
younger than 75 years of age showed no diﬀerence in
1-year overall survival between both intervals (HR
1.11; 95% CI 0.54–2.30; p = 0.8), patients P75 years
showed worse survival for the 4–7 days interval com-
pared to those with 0–3 days interval (HR 3.58; 95%
CI 1.32–9.71; p = 0.01). Adjusted for age, gender and
stage these diﬀerences remained signiﬁcant (HR 3.65;
95% CI 1.31–10.16; p = 0.01). The diﬀerence between
the two interval groups in elderly patients arose within
the ﬁrst month, which suggested non-cancer-related
mortality (including post-operative complications), astrial.
p-Value
8–27 days P28 days
n % n %
0.5
5 1.0 4 0.8
0 0.0 0 0.0
0.2
4 1.0 1 0.2
1 0.5 3 1.3
<0.001
0 0.0 2 20.0
2 0.9 2 0.9
0 0.0 0 0.0
3 1.3 0 0.0
5 0.8 4 0.6
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Fig. 2a. Comparison of one-year overall survival per interval group stratiﬁed for age group (total mesorectal excision (TME)-trial).
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Fig. 2b. Comparison of one-year non-cancer related mortality per interval group stratiﬁed for age group (total mesorectal excision (TME)-trial).
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p = 0.04). No signiﬁcant diﬀerences were found for both
age groups between the two interval groups in 5 year
disease-free survival (HR 1.00; 95% CI 0.71–1.39;
p = 0.9 for patients <75 years and HR 2.07; 95% CI
0.90–4.79; p = 0.09 for patients P75 years), neither for
the 5 year local-recurrence free survival (HR 0.79; 95%
CI 0.37–1.67; p = 0.5 for patients <75 years and HR
3.98; 95% CI 0.41–38.34; p = 0.2 for patients
P75 years).
3.2. Veriﬁcation set
3.2.1. Patients
A total of 600 patients receiving radiotherapy
between 2000 and 2010 were included in this veriﬁcation
set. The median follow-up since surgery of these patients
was 4.3 years (range 0–11.4 years). Median age of these
patients at time of surgery was 67.2 years (range 26.5–
94.5 years).3.2.2. Radiotherapy duration and interval between
radiotherapy and surgery
In this cohort most patients received radiotherapy
during 5 days (45.8%) or 7 days (50.2%) (Table 1b).
The remaining patients received radiotherapy during
6 days (0.5%) or 8 days (3.5%). Most patients (425/600)
were operated on 0–3 days after the last fraction of
radiotherapy. The interval of 4–7 days, 8–27 days and
P28 days were less common (112/600, 18/600, and 35/
600 patients, respectively). Over time there was an
increase in patients who were operated on more than
28 days after the last fraction of radiotherapy (from
2.9% in 2000, to 10.7% in 2009; p < 0.001).
As shown in Table 2b, in the veriﬁcation set elderly
patients of 75 years and older more often had an interval
of P28 days, and less often 63 days (p = 0.006).
Furthermore, with a longer interval between the last
fraction of radiotherapy and surgery, there was a
decrease in pathological stage (p < 0.001). The pooled
rate of pathological complete response in patients with
Table 2b
Clinical characteristics of patients of the veriﬁcation set.
Interval between radiotherapy and surgery p-Value
63 days 4–7 days 8–27 days P28 days
n % n % n % n %
Age 0.006
<75 years 336 72.7 95 20.6 12 2.6 19 4.1
P75 years 89 64.5 27 19.6 6 4.3 16 11.6
Sex 0.1
Male 272 74.3 64 17.5 10 2.7 20 5.5
Female 153 65.4 58 24.8 8 3.4 15 6.4
Stage <0.001
0 4 57.1 0 0.0 0 0.0 3 42.9
I 140 70.4 38 19.1 5 2.5 16 8.0
II 120 67.2 37 22.2 8 3.9 12 6.7
III 159 76.0 43 19.2 5 2.9 4 1.9
Unknown 2 33.3 4 66.7 0 0.0 0 0.0
Total 425 70.8 122 20.3 18 3.0 35 5.9
Bold values represent p < 0.05.
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patients).
3.2.3. Survival
3.2.3.1. Interval. The 30-day mortality for all ages com-
bined was 1.7% for an interval of 0–3 days, 1.6% for an
interval of 4–7 days and 2.9% for an interval of 28 days
or more, which was not statistically diﬀerent (p = 0.9).
Both the 30-day mortality and the one-year overall sur-
vival of the patients from the veriﬁcation set did not
show the age disparity found in the dataset from the
TME trial (Fig. 3a). Due to small numbers, patients
with an interval of 8 until 27 days between radiotherapy
and surgery (n = 18) were excluded from survival analy-
sis. There was no signiﬁcant diﬀerence found between
the interval of 0–3 days compared to 4–7 days both for
patients <75 years (HR 0.65; 95% CI 0.14–2.93;
p = 0.6) and patients P75 years (HR 0.59; 95% CI
0.13–2.66; p = 0.5). This remained after adjusting for
age, gender and stage. Similarly, no diﬀerences in overall0.
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Fig. 3a. Comparison of one-year overall survival per intsurvival were found between the interval of 0–3 days
and P28 days in neither patients <75 years (HR 3.70;
95% CI 0.82–16.72; p = 0.09), nor in patientsP75 years
(HR 0.97; 95% CI 0.22–4.38; p = 0.9).
The non-cancer-related survival of younger and
elderly patients showed no signiﬁcant diﬀerences between
the interval of 0–3 days compared to 4–7 days either (HR
0.40; 95% CI 0.05–3.13; p = 0.4, for patients <75 years,
and HR 1.08; 95% CI 0.22–5.36; p = 0.9, for patients
P75 years, respectively) (Fig. 3b). Besides, no diﬀerences
were found in 5 year disease-free survival (HR 0.93; 95%
CI 0.57–1.52; p = 0.8, 4–7 day interval compared to
0–3 days for patients younger than 75 years, HR 0.77;
95% CI 0.29–2.05; p = 0.6, 4–7 day interval compared
to 0–3 days for patients of 75 years and older).
Furthermore, no diﬀerences were found in 5-year
local-recurrence free survival, (HR 0.27; 95% CI
0.04–2.06; p = 0.2, HR 0.89; 95% CI 0.19–4.29;
p = 0.9, for younger and elderly patients with an interval
of 4–7 days compared to 0–3 days, respectively).0.
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Fig. 3b. Comparison of one-year non-cancer related mortality per interval group stratiﬁed for age group (veriﬁcation set).
C.B.M. van den Broek et al. / European Journal of Cancer 49 (2013) 3131–3139 31373.2.3.2. Duration of radiotherapy. Since the TME-trial
the radiotherapy treatment was more often interrupted
with a weekend, which increased the duration of radio-
therapy from 5 days (85.0% in the TME trial) to 7 days
(50.2% in the veriﬁcation set). When radiotherapy dur-
ing 5 days and during 7 days were compared in the ver-
iﬁcation set, no diﬀerences were found in 1-year overall
survival (HR 0.75; 95% CI 0.37–1.52; p = 0.4), 1-year
non-cancer-related mortality (HR 0.91; 95% CI 0.39–
2.10; p = 0.8) or 5-year local-recurrence free survival
(HR 0.89; 95% CI 0.39–2.01; p = 0.8). Furthermore,
no diﬀerences in overall survival, non-cancer-related
survival or local-recurrence free survival were found in
patients aged <75 years, neither in patients aged
P75 years.3.2.3.3. Overall treatment time. Since both the duration
of the radiotherapy and the interval between radiother-
apy and surgery have changed over time, overall treat-
ment time (OTT, as explained in Fig. 1), could have
been a factor inﬂuencing mortality. However, in the
veriﬁcation set OTT was not associated with 1-year
overall survival, 1-year non-cancer-related survival or
5-year local-recurrence free survival (HR 0.24; 95% CI
0.03–1.75; p = 0.2, HR 0.35; 95% CI 0.085–2.62;
p = 0.3 and HR 1.31; 95% CI 0.45–3.87; p = 0.6, respec-
tively). When the analyses have been done separately for
each age group (<75 years and P75 years), no diﬀer-
ences were found either.4. Discussion
In this study we analysed the impact of the interval
between the last fraction of short-course radiotherapy
and surgery on 1-year survival and long-term recur-
rence, both in the TME-trial and in a veriﬁcation set.
Results from the TME-trial showed that elderly patients
with a prolonged interval (4–7 days) between the end of
radiotherapy and surgery had higher one-year overalland non-cancer related mortality. In the veriﬁcation
set this could not be conﬁrmed.
Although the results of the TME cohort derived from
a randomised controlled trial, we have to interpret these
results with caution, since these analyses have not been
evaluated in a randomised setting. Therefore the ﬁnding
may be simply a random ﬁnding. Another possible
explanation for the results found may be that surgery
was postponed in patients with a poor condition, after
consultation by the anaesthetist, which would result in
bias. Elderly patients are expected to have a poor condi-
tion more often, which would explain that the results
were only found in patients P75 years. Because most
patients were seen by the anaesthetist during admission
prior to surgery, postponement of surgery by the anaes-
thetist should then result in a longer interval between
admission and surgery for the longer interval group.
However, no diﬀerence was found, with a similar med-
ian time between admission and surgery in both interval
groups (2 days). Furthermore, no diﬀerences were found
in age, gender, stage (see Table 2a), WHO performance
scores (data not shown) and toxicity (data not shown)
between the two interval groups. Even though, comor-
bidities were not administered during the TME trial,
and might explain diﬀerences between both interval
groups.
For this reason we tried to conﬁrm the above men-
tioned ﬁndings in a separate retrospectively collected
veriﬁcation set. In this veriﬁcation set, no diﬀerences
were found in one-year overall survival and non-can-
cer-related survival between the interval groups. Several
possible reasons could explain this. Firstly, over time
perioperative care might have improved, resulting in less
post-operative mortality. 30-day mortality was 2.1% in
the interval of 0–3 days and 4.7% in the interval of
4–7 days, compared with 1.7% in the interval of
0–3 days, 1.6% in the interval of 4–7 days and 2.9% in
the interval of 28 days or more in the veriﬁcation set;
suggestion that perioperative care has improved.
Finally, another possibility is that due to awareness of
3138 C.B.M. van den Broek et al. / European Journal of Cancer 49 (2013) 3131–3139the clinicians for the higher postoperative mortality,
since the TME results have been presented on several
congresses, elderly patients were less often treated with
an interval between 4 till 7 days between radiotherapy
and surgery in the veriﬁcation set. The results showed
that indeed fewer patients were operated on 4 till 7 days
after the last fraction of radiotherapy, indicating that
awareness of the physicians might have been present.
Besides, the ﬁnding that there has been a shift in radio-
therapy duration from mainly 5 days in the TME-trials
to 7 days in the veriﬁcation set, suggests that this was
done in order to prevent logistical problems. During
the TME trial most patients received radiotherapy from
Monday till Friday, followed by surgery in the next
week. The knowledge of possible worse outcome after
an interval of more than three days might have triggered
radiation oncologists to decrease the interval between
the end of radiotherapy and surgery, with nowadays
only 20% of patients having an interval of 4–7 days
(122 out of 600 patients), which was over 50% during
the TME-trial (340 out of 642 patients). This resulted
in a shift in approach; approximately 10% of the
patients had a radiotherapy duration of 7 days during
the TME-trial, whereas this was over 50% in the veriﬁ-
cation set. The present study therefore analysed the rela-
tion between overall treatment time and postoperative
mortality and non-cancer-related mortality, demonstrat-
ing no diﬀerence, neither for the whole group, nor for
the elderly. This suggests that including a weekend in
radiotherapy treatment is safe.
Several other studies have studied the inﬂuence of the
interval between radiotherapy and surgery. Recently the
interim analyses of the Stockholm III trial have been
published. In these interim analyses an increase in post-
operative complications for patients surgically treated
11–17 days since the start of radiotherapy compared to
patients with a shorter interval was reported. Diﬀerences
in postoperative mortality were not signiﬁcant due to
small numbers.18 Similar, Hartley et al.20 found in a ret-
rospective population-based cohort that patients with
an overall treatment time <10 days had a decreased risk
of complications. Additionally, Hartley et al.21 pub-
lished that the ratio between pre-operative and postop-
erative neutrophil leucocyte count was signiﬁcantly
higher in patients without complications. Even though,
they did not ﬁnd an association between the neutrophil
ratio and the overall treatment time. Fokstuen et al.17
found clear indications that the diﬀerences between the
interval groups are related to the perioperative leucocyte
response. Patients with an abnormal leucocyte response
developed sepsis more often and had an increased risk of
death within 90 days after surgery. Besides, a longer
than recommended interval also appeared to be
detrimental for postoperative death independently of
leucocyte response. From the above can be concluded
that there are several indications in the literature thatthe increased postoperative mortality after a longer
interval between radiotherapy and surgery could be
caused by an impaired immune response, possibly
reﬂected in the perioperative leucocyte count of the
patient.
Currently a Swedish trial studies delayed surgery
after short course radiotherapy, because clear indica-
tions have been found that short course radiotherapy
could cause downstaging after an interval between
radiotherapy and surgery of at least 4 weeks.18,22,23
Almost certainly due to these results and the currently
running trial, delayed surgery was used more often in
the veriﬁcation set, mainly in elderly patients. In our
study there were also indications that delayed surgery
induces downstaging, as patients with delayed surgery
had a lower pathological stage. Furthermore, the veriﬁ-
cation set showed no diﬀerences in short-term survival
between direct surgery after radiotherapy (interval of
0–3 days or 4–7 days) compared to delayed surgery
(interval of 28 days or more), which is in line with the
results shown in the interim analyses of the Stockholm
III trial.18 Possibly, the leucocyte response has norma-
lised at the time those patients are operated on.
In conclusion, there are several indications that the
interval between radiotherapy and surgery inﬂuences
postoperative outcome. Results from the veriﬁcation
set demonstrate that avoiding a longer interval between
radiotherapy and surgery and including a weekend in
the radiotherapy treatment seems safe, both for postop-
erative mortality as for oncological outcome. Therefore
we recommend to limit the interval to 3 days and accept
a radiotherapy duration of 7 days. If logistically impos-
sible, postponement surgery after more than 4 weeks
seems an option, although results on oncological out-
come have to be awaited.
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